Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Summary Background In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM
(NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …

Background Many therapies for heart failure (HF) have shown differential impact across the
spectrum of left ventricular ejection fraction (LVEF). Objectives In this prespecified analysis …

Background Heart failure with mildly reduced or preserved ejection fraction (hereafter
referred to as HFpEF) is the most common type of heart failure and is associated with a high …

Objective This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

Background The impact of glucagon-like peptide-1 receptor agonists on patients with heart
failure has not been fully described. Our main objective was to evaluate the safety and …